Karyopharm Therapeutics Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Karyopharm Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $574.00K, a 61.24% increase year-over-year.
- Karyopharm Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $405.00K, a 40.44% decline year-over-year.
- Karyopharm Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00.
- Karyopharm Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $356.00K, a 53.89% decline year-over-year.
- Karyopharm Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $761.00K, a 47.59% decline from fiscal 2024.
- Karyopharm Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.45M, a 29.18% increase from fiscal 2023.
- Karyopharm Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $1.12M, a 71.74% decline from fiscal 2022.
- Karyopharm Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $3.98M, a 6.19% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $574.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $405.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $761.00K 10-K · filed 2026-02-13 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | |
| 2025-06-30 | $356.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $680.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $1.45M 10-K · filed 2026-02-13 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | |
| 2024-06-30 | $772.00K 10-Q · filed 2025-08-11 | |
| 2023-12-31 | $264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $1.12M 10-K · filed 2026-02-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | |
| 2023-06-30 | $860.00K 10-Q · filed 2024-08-06 | |
| 2022-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $3.98M 10-K · filed 2025-02-19 |
| 2022-09-30 | $11.00K 10-Q · filed 2023-11-02 | $3.71M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $1.33M 10-Q · filed 2023-08-02 | $3.71M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.47M 10-Q · filed 2023-05-04 | $4.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $896.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.75M 10-K · filed 2024-02-29 |
| 2021-09-30 | $16.00K 10-Q · filed 2022-11-03 | $6.84M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $2.06M 10-Q · filed 2022-08-04 | $8.07M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $773.00K 10-Q · filed 2022-05-05 | $8.35M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $3.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $10.31M 10-K · filed 2023-02-17 |
| 2020-09-30 | $1.24M 10-Q · filed 2021-11-03 | $9.69M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $2.34M 10-Q · filed 2021-08-05 | $9.03M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $2.73M 10-Q · filed 2021-05-04 | $7.09M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.50M 10-K · filed 2022-03-01 |
| 2019-09-30 | $577.00K 10-Q · filed 2020-11-02 | $2.02M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $395.00K 10-Q · filed 2020-08-04 | $2.25M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $152.00K 10-Q · filed 2020-05-05 | $3.27M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $892.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $3.52M 10-K · filed 2021-02-24 |
| 2018-09-30 | $812.00K 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $1.41M 10-Q · filed 2019-08-07 | |
| 2018-03-31 | $429.00K 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $858.00K 10-K · filed 2020-02-26 | |
| 2016-12-31 | $630.00K 10-K · filed 2019-02-28 | |
| 2015-12-31 | $616.00K 10-K · filed 2018-03-15 | |
| 2014-12-31 | $284.00K 10-K · filed 2017-03-16 | |
| 2013-12-31 | $34.00K 10-K · filed 2016-03-15 | |
| 2012-12-31 | $9.00K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |